院前大剂量甲泼尼龙用于复苏后院外心脏骤停患者(STEROHCA):一项随机临床试验
STEROHCA是一项在丹麦两个心脏骤停中心进行的随机、盲法、安慰剂对照II期院前试验,纳入137例疑似心源性病因的复苏后昏迷院外心脏骤停患者,1:1随机接受单次静脉注射甲泼尼龙250 mg(n=68)或安慰剂(n=69)。共同主要终点为入院后72小时内每日测量的IL-6和NSE血液水平降低。结果显示干预组IL-6水平显著降低(p<0.0001),24小时中位数(IQR)为2.1 pg/ml(1.0; 7.1),安慰剂组为30.7 pg/ml(14.2; 59);两组NSE水平无差异(p=0.22),48小时干预组为18.8 ug/L(14.4; 24.6),安慰剂组为14.8 ug/L(11.2; 19.4)。干预组51例(75%)存活,安慰剂组44例(64%)存活。
要点
- 院前单次静脉注射甲泼尼龙250 mg使复苏后昏迷OHCA患者24小时IL-6中位数降至2.1 pg/ml(IQR 1.0; 7.1),安慰剂组为30.7 pg/ml(IQR 14.2; 59),p<0.0001。
- 甲泼尼龙未降低NSE水平(p=0.22),48小时干预组18.8 ug/L(IQR 14.4; 24.6),安慰剂组14.8 ug/L(IQR 11.2; 19.4)。
- 180天生存率:干预组51例(75%)存活,安慰剂组44例(64%)存活。
适用人群与场景
- 纳入:在丹麦两个心脏骤停中心、院前环境中,疑似心源性病因的复苏后昏迷院外心脏骤停患者。
处置流程与药物剂量
- 干预:单次静脉注射甲泼尼龙250 mg,院前给药。
- 对照:单次静脉注射安慰剂,院前给药。
研究设计与关键结果
- 研究设计:随机、盲法、安慰剂对照II期院前试验,在丹麦两个心脏骤停中心进行,纳入137例患者,1:1随机分入甲泼尼龙组(n=68)或安慰剂组(n=69)。
- 共同主要终点:入院后72小时内每日测量IL-6和NSE血液水平;干预组IL-6水平降低(p<0.0001),24小时中位数(IQR)为2.1 pg/ml(1.0; 7.1),安慰剂组为30.7 pg/ml(14.2; 59)。
- NSE水平两组无差异(p=0.22),48小时干预组为18.8 ug/L(IQR 14.4; 24.6),安慰剂组为14.8 ug/L(IQR 11.2; 19.4)。
- 主要次要终点:180天随访生存率,干预组51例(75%)存活,安慰剂组44例(64%)存活。
证据类型、等级与局限
- 证据类型:随机、盲法、安慰剂对照II期院前试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:对复苏后昏迷的院外心脏骤停患者进行院前大剂量甲泼尼龙治疗,可降低24小时后IL-6水平,但未降低NSE水平。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Patients who are successfully resuscitated following out-of-hospital cardiac arrest (OHCA) are still at a high risk of neurological damage and death. Inflammation and brain injury are components of the post-cardiac arrest syndrome, and can be assessed by systemic interleukin 6 (IL-6) and neuron-specific enolase (NSE). Anti-inflammatory treatment with methylprednisolone may dampen inflammation, thereby improving outcome. This study aimed to determine if prehospital high-dose methylprednisolone could reduce IL-6 and NSE in comatose OHCA patients.
METHODS: The STEROHCA trial was a randomized, blinded, placebo-controlled, phase II prehospital trial performed at two cardiac arrest centers in Denmark. Resuscitated comatose patients with suspected cardiac etiology were randomly assigned 1:1 to a single intravenous injection of 250 mg methylprednisolone or placebo. The co-primary outcome was reduction of IL-6 and NSE-blood levels measured daily for 72 h from admission. The main secondary outcome was survival at 180 days follow-up.
RESULTS: We randomized 137 patients to methylprednisolone (n = 68) or placebo (n = 69). We found reduced IL-6 levels (p < 0.0001) in the intervention group, with median (interquartile range, IQR) levels at 24 h of 2.1 pg/ml (1.0; 7.1) and 30.7 pg/ml (14.2; 59) in the placebo group. We observed no difference between groups in NSE levels (p = 0.22), with levels at 48 h of 18.8 ug/L (14.4; 24.6) and 14.8 ug/L (11.2; 19.4) in the intervention and placebo group, respectively. In the intervention group, 51 (75%) patients survived and 44 (64%) in the placebo group.
CONCLUSION: Prehospital treatment with high-dose methylprednisolone to resuscitated comatose OHCA patients, resulted in reduced IL-6 levels after 24 h, but did not reduce NSE levels.
参考来源
- Obling LER, Beske RP, Meyer MAS, et al. Prehospital high-dose methylprednisolone in resuscitated out-of-hospital cardiac arrest patients (STEROHCA): a randomized clinical trial. Intensive Care Med. 2023. PMID: 37943300. doi:10.1007/s00134-023-07247-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。